Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Eli Lilly and Company furnished an 8-K under Item 2.02 to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into Item 2.02.
The information in Item 2.02 is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also includes Exhibit 104 for the cover page Inline XBRL. The document identifies Lilly’s listed securities, including common stock (LLY) on the NYSE.
Adverum Biotechnologies (ADVM) is the target of a planned tender offer by Eli Lilly and Company via its wholly owned subsidiary, Flying Tigers Acquisition Corporation, under an Agreement and Plan of Merger dated October 24, 2025.
The tender offer has not yet commenced. Upon commencement, Lilly and its subsidiary will file tender offer materials on Schedule TO, and Adverum will file a Schedule 14D-9 to provide its position. These documents will be available on the SEC’s website and at Lilly’s investor site, and mailed to stockholders at no charge.
The communication includes forward-looking statements noting uncertainties around closing, potential contingent consideration, and availability of financing under a promissory note. Completion of the acquisition is not guaranteed and remains subject to customary conditions.
Adverum Biotechnologies (ADVM) is the target of a planned tender offer by Eli Lilly and Company via its wholly owned subsidiary, Flying Tigers Acquisition Corporation, under an Agreement and Plan of Merger dated October 24, 2025.
The tender offer has not yet commenced. Upon commencement, Lilly and its subsidiary will file tender offer materials on Schedule TO, and Adverum will file a Schedule 14D-9 to provide its position. These documents will be available on the SEC’s website and at Lilly’s investor site, and mailed to stockholders at no charge.
The communication includes forward-looking statements noting uncertainties around closing, potential contingent consideration, and availability of financing under a promissory note. Completion of the acquisition is not guaranteed and remains subject to customary conditions.
Eli Lilly (LLY) reported an insider transaction by a director on 10/20/2025. The filing shows an acquisition of 6.129 shares of common stock at $808.96 per share, bringing the director’s direct beneficial ownership to 2,728.14 shares.
According to the footnote, the acquired amount was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person’s separation from service.
Eli Lilly (LLY) director reported a routine equity accrual. On 10/20/2025, the director acquired 18.336 shares of common stock at $808.96 per share, recorded as an “A” (acquisition). Following this transaction, the director beneficially owns 16,474.296 shares, held directly.
The filing notes these shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common shares after the director’s separation from service.
Eli Lilly (LLY) director Mary Lynne Hedley reported an acquisition of 12.259 shares of common stock on 10/20/2025 at $808.96 per share. The filing states the shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common stock following her separation from service.
After the transaction, beneficial ownership stood at 2,015.828 shares held directly and 98 shares held indirectly by trust.
Eli Lilly (LLY) director transaction: On 10/20/2025, director J. Erik Fyrwald reported acquiring 12.259 shares at $808.96. The filing notes the director elected to defer cash compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in common shares after separation from service. Following the entry, beneficial ownership stands at 74,763.656 shares, held directly.
Eli Lilly (LLY) director reported acquiring 14.525 shares of common stock on 10/20/2025 at $808.96 per share. The award was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares following the director’s separation from service. After the transaction, beneficial ownership was 55,151.946 shares directly and 758 shares indirectly by trust.
Eli Lilly (LLY) insider transaction: A reporting person disclosed open‑market sales of Eli Lilly common stock on 10/10/2025. The filer sold 468 shares at a weighted average price of $862.34 (prices ranged from $862.00 to $862.74) and 3,190 shares at a weighted average price of $863.369 (prices ranged from $863.00 to $863.995). Following these transactions, the filer directly owned 94,533,320 shares. The form was signed by Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc.
Lilly Endowment Inc., a director-related reporting person, sold a total of 10,602 shares of Eli Lilly & Co common stock on 10/09/2025. The Form 4 lists eight separate sale entries with weighted-average prices for each block; the reported trade price ranges span from $848.09 up to $857.26. After these transactions, the reporting person beneficially owns 94,536,978 shares directly. Each sale line notes the reporting person can provide detailed per-price quantities on request, and the Form 4 was signed by Peter A. Buck on behalf of Lilly Endowment Inc.
Form 144 notice for Eli Lilly & Co (LLY) records a proposed sale of 305,000 shares of Common Stock through J.P. Morgan Securities LLC with an aggregate market value of $260,881,750 and an approximate sale date of 10/10/2025. The filing lists 946,456,759 shares outstanding for the class. The shares to be sold were acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust, showing an original acquired amount of 38,400,000 shares.
The notice also discloses multiple recent sales by Lilly Endowment Inc., including 280,000 shares sold on 07/24/2025 for $225,419,292 and a series of sales from 09/18/2025 through 10/09/2025 with individual proceeds reported. The signer certifies no undisclosed material adverse information and complies with Rule 144 procedural disclosure.